See more : Souyute Group Co.,Ltd (002503.SZ) Income Statement Analysis – Financial Results
Complete financial analysis of Adaptive Biotechnologies Corporation (ADPT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Adaptive Biotechnologies Corporation, a leading company in the Biotechnology industry within the Healthcare sector.
- On4 Communications, Inc. (ONCI) Income Statement Analysis – Financial Results
- Entest Group, Inc. (ETNI) Income Statement Analysis – Financial Results
- PT Berdikari Pondasi Perkasa Tbk (BDKR.JK) Income Statement Analysis – Financial Results
- Dare Power Dekor Home Co.,Ltd. (000910.SZ) Income Statement Analysis – Financial Results
- JinGuan Electric Co., Ltd. (688517.SS) Income Statement Analysis – Financial Results
Adaptive Biotechnologies Corporation (ADPT)
About Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ, a platform and core immunosequencing product that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signals; and T-Detect COVID for the confirmation of past COVID-19 infection. It also provides clonoSEQ, a clinical diagnostic product for the detection and monitoring of minimal residual disease in patients with multiple myeloma, B cell acute lymphoblastic leukemia, and chronic lymphocytic leukemia, as well as available as a CLIA-validated laboratory developed test for patients with other lymphoid cancers; and immunoSEQ T-MAP COVID for vaccine developers and researchers to measure the T-cell immune response to vaccines. In addition, the company offers a pipeline of clinical products and services that are used for the diagnosing, monitoring, and treatment of diseases, such as cancer, autoimmune conditions, and infectious diseases. It serves the life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 170.28M | 185.31M | 154.34M | 98.38M | 85.07M | 55.66M | 38.45M |
| Cost of Revenue | 75.55M | 57.91M | 49.30M | 22.53M | 22.27M | 19.67M | 15.68M |
| Gross Profit | 94.72M | 127.40M | 105.04M | 75.85M | 62.80M | 36.00M | 22.77M |
| Gross Profit Ratio | 55.63% | 68.75% | 68.06% | 77.10% | 73.82% | 64.67% | 59.22% |
| Research & Development | 122.12M | 141.76M | 142.34M | 116.07M | 70.71M | 39.16M | 32.00M |
| General & Administrative | 83.93M | 88.53M | 74.50M | 49.54M | 30.33M | 20.41M | 15.95M |
| Selling & Marketing | 88.58M | 95.60M | 95.47M | 61.36M | 38.45M | 24.49M | 16.77M |
| SG&A | 172.51M | 184.13M | 169.97M | 110.89M | 68.79M | 44.90M | 32.71M |
| Other Expenses | 27.13M | 1.70M | 1.70M | 1.70M | 1.70M | 1.70M | 1.69M |
| Operating Expenses | 321.76M | 327.59M | 314.01M | 228.67M | 141.19M | 85.75M | 66.40M |
| Cost & Expenses | 397.31M | 385.49M | 363.31M | 251.20M | 163.46M | 105.42M | 82.08M |
| Interest Income | 15.53M | 4.06M | 1.67M | 6.59M | 9.79M | 3.31M | 1.64M |
| Interest Expense | 13.80M | 4.24M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 22.23M | 28.15M | 20.98M | 11.74M | 7.79M | 6.00M | 5.80M |
| EBITDA | -189.27M | -167.98M | -193.35M | -144.35M | -70.60M | -43.76M | -37.84M |
| EBITDA Ratio | -111.16% | -104.92% | -134.29% | -153.60% | -90.15% | -78.61% | -96.23% |
| Operating Income | -227.04M | -200.19M | -208.97M | -152.82M | -78.39M | -49.76M | -44.48M |
| Operating Income Ratio | -133.33% | -108.03% | -135.39% | -155.33% | -92.15% | -89.39% | -115.68% |
| Total Other Income/Expenses | 1.73M | -182.00K | 1.67M | 6.59M | 9.79M | 3.31M | 1.64M |
| Income Before Tax | -225.30M | -200.37M | -207.30M | -146.23M | -68.61M | -46.45M | -42.83M |
| Income Before Tax Ratio | -132.32% | -108.13% | -134.31% | -148.63% | -80.65% | -83.44% | -111.40% |
| Income Tax Expense | 0.00 | -57.90M | -1.69M | -6.59M | -9.79M | 3.31M | -804.00K |
| Net Income | -225.25M | -142.46M | -205.61M | -139.64M | -58.82M | -46.45M | -42.83M |
| Net Income Ratio | -132.29% | -76.88% | -133.22% | -141.93% | -69.14% | -83.44% | -111.40% |
| EPS | -1.56 | -1.00 | -1.46 | -1.06 | -0.85 | -0.44 | -0.41 |
| EPS Diluted | -1.56 | -1.00 | -1.46 | -1.06 | -0.85 | -0.44 | -0.41 |
| Weighted Avg Shares Out | 144.38M | 142.52M | 140.35M | 131.22M | 69.17M | 105.43M | 105.43M |
| Weighted Avg Shares Out (Dil) | 144.38M | 142.52M | 140.35M | 131.22M | 69.17M | 105.43M | 105.43M |
Adaptive Biotechnologies (ADPT) Reports Q1 Loss, Tops Revenue Estimates
Is Adaptive Biotechnologies (ADPT) Stock Outpacing Its Medical Peers This Year?
Adaptive Biotechnologies to Report First Quarter Financial Results on May 3, 2023
How Much Upside is Left in Adaptive Biotechnologies (ADPT)? Wall Street Analysts Think 49.94%
Is Adaptive Biotechnologies (ADPT) Stock Outpacing Its Medical Peers This Year?
Can Adaptive Biotechnologies (ADPT) Climb 45.58% to Reach the Level Wall Street Analysts Expect?
Adaptive Biotechnologies Corporation (ADPT) Q4 2022 Earnings Call Transcript
Adaptive Biotechnologies (ADPT) Reports Q4 Loss, Lags Revenue Estimates
Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2022 Financial Results on February 14, 2023
Adaptive Biotechnologies to Present at the 41st Annual J.P. Morgan Healthcare Conference
Source: https://incomestatements.info
Category: Stock Reports